Inipharm
Developing Treatments for Severe Liver Disease
- Website
- inipharm.com
- Total Funding
- $35.0M
- Last Round
- $35.0M Series A
- Rounds
- 1
About
Inipharm is a clinical-stage biopharmaceutical company developing therapies for severe liver diseases. Its lead program, INI-822, is a first-in-class small-molecule inhibitor of HSD17B13, a genetically defined target associated with chronic liver disease. Through its Australian subsidiary, the company is conducting a Phase 1 trial that includes patients with MASH while advancing additional small-molecule therapies against the same target.
Summary
Inipharm is a Biotech company. It has raised $35.0M in total across 1 round. Investors include 5AM Ventures, Wu Capital and Frazier Healthcare.
Tech & App Stack
1 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Unknown
Investors
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Specialty pharmaceutical company
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Altos Labs combines academic science and industry development to create medicines that restore ce...
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/inipharm"><img src="https://indexed.vc/api/badge/company/inipharm" alt="Inipharm on Indexed.vc" width="260" height="76" /></a>